Apelin as a Marker of Early Complications in Type 1 Diabetes Mellitus
1 other identifier
observational
90
0 countries
N/A
Brief Summary
Aims of the Research :
- 1.assessment of serum apelin levels in patients with T1DM with comparison to non-diabetic controls.
- 2.investigate the relation between serum apelin levels and glycemic balance.
- 3.clarify the the relation between serum apelin and lipid concentrations.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2023
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 12, 2023
CompletedFirst Posted
Study publicly available on registry
February 22, 2023
CompletedStudy Start
First participant enrolled
February 25, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedFebruary 22, 2023
January 1, 2023
1.8 years
January 12, 2023
February 12, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
glycemic control according to apelin level
baseline
Secondary Outcomes (1)
Detection of the relation of apelin and lipid profile in diabetic patients
baseline
Study Arms (2)
1
patients with type 1 diabetes aged 20-30 years
2
healthy people serve as controls of the same age group
Eligibility Criteria
60 patients with Type 1 Diabetes Mellitus and 30 healthy individuals of the same age group serve as a control group.
You may qualify if:
- type 1 diabetic patients (treated with insulin ). age between 20 to 30 years , including males and females.
- And accepting participation in the study.
You may not qualify if:
- patients with acute illness.and pregnancy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (2)
Al-Selwi Y, Shaw JA, Kattner N. Understanding the Pancreatic Islet Microenvironment in Cystic Fibrosis and the Extrinsic Pathways Leading to Cystic Fibrosis Related Diabetes. Clin Med Insights Endocrinol Diabetes. 2021 Oct 12;14:11795514211048813. doi: 10.1177/11795514211048813. eCollection 2021.
PMID: 34675737BACKGROUNDSabry RN, El Wakeel MA, El-Kassas GM, Amer AF, El Batal WH, El-Zayat SR, Abou-El-Asrar M. Serum Apelin: A New Marker of Early Atherosclerosis in Children with Type 1 Diabetes Mellitus. Open Access Maced J Med Sci. 2018 Apr 4;6(4):613-617. doi: 10.3889/oamjms.2018.144. eCollection 2018 Apr 15.
PMID: 29731925BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- resident doctor
Study Record Dates
First Submitted
January 12, 2023
First Posted
February 22, 2023
Study Start
February 25, 2023
Primary Completion
December 1, 2024
Study Completion
December 1, 2025
Last Updated
February 22, 2023
Record last verified: 2023-01